Abstract:ID 130936 Poster Board 493 The receptor for pituitary adenylate cyclase-activating polypeptide (PACAP) is a Gs-coupled GPCR, designated PAC1. Antagonists of this receptor are being pursued for their potential to ameliorate atherosclerogenesis, depression, post-traumatic stress disorder, and migraine; discovery of agonists is also of interest for counteracting the neurodegenerative consequences of stroke and ischemia. However, obtaining small-molecule ligands (SMOLs) for this receptor has been challenging. Peptide-based antagonists include an N-terminally truncated version of PACAP38 (P38) itself, PACAP6-38 (P6-38). The activity of P6-38 as an antagonist is consistent with models of PACAP binding to PAC1 in which the N-terminus of PACAP is required for receptor activation leading to signaling through the Gs protein, while the C-terminus is involved in initial binding (affinity-trapping) to PAC1. P6-38 has been shown repeatedly to block the action of P38 as well as the naturally occurring ligand PACAP1-27 (P27) both in vivo and in cells expressing endogenous PAC1. Several SMOLs reported to be PAC1 antagonists in the literature were tested for antagonist activity in HEK293 cells expressing the human PAC1 receptor and a cAMP biosensor (CBS)-based cAMP detection system; however not only these but also P6 -38 were without inhibitory effect in this assay system. Accordingly, we re-tested the inhibitory activity of P6-38 against both P27 and P38 in cells expressing CBS but with native expression of PAC1: the rat NS-1 pheochromocytoma cell line, and the human SH-SY5Y neuroblastoma cell line. Both CBS-based luminescent read-out, and generation of cAMP provoked by exposure to EC50 concentrations of P27 or P38 (0.2 nM) were blocked by 1 mM P6-38 which also blocked downstream signaling effects (neuritogenesis) of P27 and P38. Recently, cryo-EM structures of a number of family B (secretin family) GPCR-ligand structures have been obtained, allowing detailed molecular dynamics analysis of ligand-receptor binding, and prediction of residues contributing most strongly to ligand engagement. Molecular dynamics simulations predicted initial receptor engagement with residues 6-30, but not 31-38, of P38. Accordingly, we synthesized a series of deletants of PACAP6-38 and tested their relative inhibitory potency in SH-SY5Y and NS-1 cells. PACAP6-30 (IC50 ~33 nM) was nearly as potent as PACAP6-38 (IC50 ~21 nM) as an inhibitor of cyclic AMP elevation by 0.2 nM P38 (the approximate EC50 for both the CBS-based and the direct cAMP assay, both carried out in the presence of phosphodiesterase inhibition by IBMX). PACAP6-27 was considerably less potent (IC 50 >10 mM). Thus, the affinity-trap model for PAC1-ligand interaction successfully predicts the behavior of peptide-based inhibitors of P27 and P38 engagement with an endogenously expressed PAC1 receptor. We are currently engaged in peptide modification of P6-30 in order to increase the potency of this PAC1 antagonist.

Possible key residues that determine left gastric artery blood flow response to PACAP in dogs

Identification of key residues that cause differential gallbladder response to PACAP and VIP in the guinea pig

Neuropeptide Pacap in Mouse Liver Ischemia and Reperfusion Injury: Immunomodulation by the Camp-Pka Pathway

Understanding VPAC receptor family peptide binding and selectivity

PACAP Deletants as Peptide-based PACAP Antagonists

Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice

Molecular Basis of Class B GPCR Selectivity for the Neuropeptides PACAP and VIP

Effects of Inhibition of Alpha-Cgrp Receptors on Cardiac and Peripheral Vascular Dynamics in Conscious Dogs with Chronic Heart Failure.

VPAC1 and VPAC2 receptors mediate tactile hindpaw hypersensitivity and carotid artery dilatation induced by PACAP38 in a migraine relevant mouse model

TAT-tagging of VIP exerts positive allosteric modulation of the PAC1 receptor and enhances VIP neuroprotective effect in the MPTP mouse model of Parkinson's disease

Signal Transduction by VIP and PACAP Receptors

Toward the Three-Dimensional Structure and Lysophosphatidic Acid Binding Characteristics of the LPA(4)/p2y(9)/GPR23 Receptor: a Homology Modeling Study.

PACAP38 Differentially Effects Genes and CRMP2 Protein Expression in Ischemic Core and Penumbra Regions of Permanent Middle Cerebral Artery Occlusion Model Mice Brain

VIP and PACAP

PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model

Investigating the impact of PACAP on thermal stability of G-actin by differential scanning calorimetry

Pharmacological and functional characterization of galanin-like peptide fragments as potent galanin receptor agonists

Exploring the Role of Neuropeptide PACAP in Cytoskeletal Function Using Spectroscopic Methods

Positive allosteric regulation of PAC1-R up-regulates PAC1-R and its specific ligand PACAP

Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors

Comparing The Impact of Systemic Pituitary Adenylate-Cyclase-Activating Polypeptide (PACAP) and Calcitonin Gene-Related Peptide (CGRP) on Motion-Induced Nausea And Balance Behaviors In Mice